AbbVie Inc won a trade secrets case against a Botox rival, with an order that calls for U.S. imports of the Jeuveau wrinkle treatment to be halted for 21 months.

The U.S. International Trade Commission on Wednesday upheld a judge’s finding that Evolus Inc. and its partner Daewoong Pharmaceutical Co. made their treatment with a secret process stolen from AbbVie’s South Korean partner. The ruling reduces an initial 10-year ban proposed by the judge.

Read the full article at